A Comparison of Coverage Restrictions for Biopharmaceuticals and Medical Procedures.

[1]  D. Malone,et al.  Is Real-World Evidence Used in P&T Monographs and Therapeutic Class Reviews? , 2017, Journal of managed care & specialty pharmacy.

[2]  Colby L. Wilkinson,et al.  Variation in Private Payer Coverage of Rheumatoid Arthritis Drugs , 2016, Journal of managed care & specialty pharmacy.

[3]  P. Neumann,et al.  Mapping US commercial payers' coverage policies for medical interventions. , 2016, The American journal of managed care.

[4]  P. Neumann,et al.  Private payers disagree with Medicare over medical device coverage about half the time. , 2015, Health affairs.

[5]  Joshua T. Cohen,et al.  Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. , 2014, The New England journal of medicine.

[6]  M. Halpern,et al.  Pharmaceutical Technology Assessment: Perspectives from Payers , 2012, Journal of managed care pharmacy : JMCP.

[7]  A. Holtorf,et al.  Current and Future Use of HEOR Data in Healthcare Decision-Making in the United States and in Emerging Markets. , 2012, American health & drug benefits.

[8]  P. Neumann,et al.  Skills of the Trade: The Tufts Cost-Effectiveness Analysis Registry , 2012, Journal of Benefit-Cost Analysis.

[9]  Kathryn R. Fingar,et al.  Most Frequent Operating Room Procedures Performed in U.S. Hospitals, 2003–2012 , 2014 .

[10]  Mark Shanley,et al.  Determinants of HMO formulary adoption decisions. , 2003, Health services research.

[11]  George G. Lorentz,et al.  ROLLE THEOREM METHOD IN SPLINE INTERPOLATION , 1983 .